ARA-290
Also known as: cibinetide, pHBSP, pyroglutamate helix B surface peptide, ARA290, ARA 290, helix B surface peptide, HBSP
Non-hematopoietic erythropoietin-derived peptide / Innate Repair Receptor (IRR) agonist
What it is
Researchers and clinicians in some countries are studying ARA-290 for neuropathic pain and small fiber neuropathy, particularly in people with sarcoidosis or diabetes. It activates a protective pathway that helps repair and reduce inflammation in nerves and organs. Not FDA-approved; WADA-prohibited; completed Phase 2 studies with promising results.
The scientific side
ARA-290 is an 11-amino acid linear non-hematopoietic peptide modeled from the three-dimensional structure of the helix B region of erythropoietin (EPO). It selectively binds and activates the innate repair receptor (IRR), a heterodimeric complex composed of the EPO receptor (EPOR) and the β-common receptor (CD131/βcR), which is pharmacologically distinct from the EPOR homodimer that mediates erythropoiesis. The IRR is typically not expressed by normal tissues but is rapidly induced by injury or inflammation. ARA-290 activation of the IRR triggers anti-inflammatory, anti-apoptotic, antioxidant, and tissue-protective signaling cascades — including inhibition of NF-κB, modulation of JAK2/PI3K-AKT pathways, and suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) — without stimulating erythropoiesis or the hematopoietic side effects associated with native EPO. A short plasma half-life (~2 minutes) has been reported, yet the peptide activates a molecular switch that triggers sustained biological effects. ARA-290 also directly inhibits TRPV1 channel activity, providing an additional peripheral analgesic mechanism. Through βCR-dependent signaling, it suppresses spinal microglia activation, reduces allodynia, and promotes small nerve fiber regeneration.
Class: Non-hematopoietic erythropoietin-derived peptide / Innate Repair Receptor (IRR) agonist
Legal & regulatory status
Not approved; described in reviewed literature as unapproved by the U.S. Food and Drug Administration. Listed as a prohibited substance by WADA and subject to sports doping detection methods.
Prohibited; listed on the WADA prohibited substances list and subject to mandatory doping control screening
Not stated in reviewed literature — requires manual verification
What it's studied for
- Sarcoidosis-associated small fiber neuropathy (SFN) and neuropathic pain Human RCT
- Randomized, double-blind pilot study (n=22 sarcoidosis patients with SFN): 3×/week IV ARA-290 2 mg for 4 weeks significantly improved small fiber neuropathy screening list (SFNSL) score vs. placebo (Δ −11.5 vs. −2.9, p<0.05). Pain and physical functioning dimensions of SF-36 also significantly improved. No safety conce PMID 23168581 Heij et al., Molecular Medicine 2012
- Blinded, placebo-controlled trial: 28 days of daily subcutaneous ARA-290 in sarcoidosis patients with documented SNFLD significantly improved neuropathic symptoms, increased corneal small nerve fiber density, changed cutaneous temperature sensitivity, and increased exercise capacity (6-minute walk test). PMID 24136731 Dahan et al., Molecular Medicine 2013
- Phase 2b, 28-day RCT (n=64, sarcoidosis-associated SNFL and neuropathic pain): cibinetide 4 mg/day significantly increased corneal nerve fiber area (CNFA) (placebo-corrected mean change 697 µm², 95% CI 159–1236, P=0.012) and intraepidermal GAP-43+ fibers (P=0.035). Pain improved in all groups; CNFA changes correlated w PMID 28475703 Culver et al., Investigative Ophthalmology & Visual Science 2017
- Review of two Phase II clinical trials: ARA-290 treatment consistently associated with significant improvement of neuropathic pain symptoms, decreases in pain scores, increases in corneal nerve fibers, improved sensory pain thresholds, improved quality of life and physical functioning in sarcoidosis patients. PMID 24555851 van Velzen et al., Expert Opinion on Investigational Drugs 2014
- Type 2 diabetes — metabolic control and peripheral neuropathy Human RCT
- Phase 2 controlled clinical trial: ARA-290 4 mg subcutaneously daily for 28 days in subjects with type 2 diabetes and painful neuropathy. No safety issues identified. Subjects receiving ARA-290 showed improved HbA1c and lipid profiles throughout 56-day observation, and neuropathic symptoms (PainDetect) significantly im PMID 25387363 Brines et al., Molecular Medicine 2015
- Neuropathic pain (animal models — nerve injury, neuritis, allodynia) Animal studies only
- In spared nerve injury rats, ARA-290 (3, 10, 30, 60 µg/kg) administered on days 1, 3, 6, 8, 10 dose-dependently reduced mechanical and cold allodynia up to 20 weeks, coupled with suppression of spinal microglia reactivity (iba-1-IR). PMID 24529189 Swartjes et al., Molecular Pain 2014
- In the neuritis model in rats, ARA-290 (30 or 120 µg/kg IP daily from day 1) prevented development of mechanical allodynia. Did not significantly affect heat hyperalgesia or CCL2/TNF-α mRNA levels. PMID 23262243 Pulman et al., Neuroscience 2013
- ARA-290 specifically inhibited TRPV1 channel activity and relieved capsaicin-induced mechanical hypersensitivity in mice, suggesting a direct peripheral analgesic mechanism distinct from IRR-mediated anti-inflammatory effects. PMID 26774587 Zhang et al., Peptides 2016
- Renal ischemia-reperfusion injury / kidney transplantation protection Animal studies only
- In pigs with unilateral renal ischemia (45 min), IV ARA-290 at 0, 2, 4, and 6 hours post-reperfusion increased GFR during 7-day observation, tended to reduce MCP-1 and IL-6 expression, and reduced interstitial fibrosis. PMID 23302512 van Rijt et al., Journal of Translational Medicine 2013
- In rat unilateral renal ischemia (30 min), early ARA-290 administration (1 hour post-reperfusion) improved renal function and reduced renal inflammation and AKI at 3 days. Late or repetitive treatment did not affect inflammation or AKI markers. PMID 24225194 van Rijt et al., Journal of Translational Medicine 2013
- In vitro (HEK-293 and ACHN cells): ARA-290 (50–400 nM) pretreatment significantly reduced cisplatin-induced DNA damage, oxidative stress (MDA/ROS), pro-inflammatory cytokines (TNFα, IL-6, IL-1β), and apoptosis (caspase-3, Bax), while increasing Bcl2 expression. PMID 36085231 Ghassemi-Barghi et al., Inflammation 2023
- Pancreatic islet transplantation protection Mixed
- ARA-290 (120 µg/kg IP) protected mouse pancreatic islets from cytokine-induced damage/apoptosis in vitro and significantly improved blood glucose after marginal PITx in streptozotocin-diabetic mice vs. controls (P<0.001). PMID 26683514 Watanabe et al., Transplantation 2016
- Cibinetide (120 µg/kg) perioperative and daily for 14 days in allogeneic mouse PITx significantly delayed allograft loss; combination with low-dose tacrolimus (0.4 mg/kg/day days 4–14) significantly improved long-term graft survival. PMID 32345869 Yao et al., Transplantation 2020
- Cibinetide maintained human islet ATP levels and reduced caspase 3/7 activity during culture with pro-inflammatory cytokines, improved insulin secretion, reduced IBMIR-induced platelet consumption in PVC loop system, and improved engraftment of human islets into athymic mice with reduced CD11b+ cell infiltration. PMID 34498509 Yao et al., Cell Transplantation 2021
- Diabetic wound healing Animal studies only
- Cibinetide 30 µg/kg subcutaneously daily in db/db diabetic mice significantly improved wound healing: increased VEGF, pAkt, p-eNOS, nitrite/nitrate; reduced MDA; improved re-epithelialization, angiogenesis, and wound breaking strength. PMID 29223734 Bitto et al., Biochimica et Biophysica Acta 2018
- ARA290-ELP fusion accelerated healing in full-thickness diabetic wound model by increasing angiogenesis; co-delivery with KGF-ELP at 1:4 ratio was the most effective treatment with fastest healing rate and thicker granulation tissue at 28 days. PMID 28688286 Devalliere et al., Biomaterials 2017
- Experimental autoimmune conditions (EAE, EAN, SLE, colitis) Animal studies only
- ARA-290 (35, 70 µg/kg IP once daily from Day 7–18 or Day 9–19) in EAE Lewis rats significantly reduced clinical severity, shortened disease duration, reduced inflammatory cell accumulation, suppressed pro-inflammatory mRNA (IL-1β, IL-17, TNF-α, IFN-γ, iNOS, MMP9), and shifted T-cells toward Th2/Treg polarization. PMID 24518674 Chen et al., Journal of Neuroimmunology 2014
- In experimental autoimmune neuritis rats, ARA-290 improved recovery, nerve regeneration and remyelination, suppressed nerve inflammation, increased Foxp3+/CD4+ Treg and Th2 cells, decreased Th1 cells, inhibited inflammatory macrophage activation, and promoted Schwann cell proliferation without inducing hematopoiesis. PMID 24603865 Liu et al., PLoS One 2014
- Cibinetide and EPO both ameliorated the clinical course of DSS-induced colitis in mice (improved weight gain and survival), with reduced inflammatory mediator production. Anti-inflammatory effects of cibinetide were dependent on CD131 and JAK2 functionality via inhibition of NF-κB p65. PMID 29026145 Nairz et al., Scientific Reports 2017
- ARA-290 administration in pristane-induced SLE and MRL/lpr mice suppressed ANAs, anti-dsDNA antibodies, reduced IgG/C3 deposition, ameliorated nephritis, reduced IL-6, MCP-1, and TNF-α, decreased renal apoptotic cells, and did not induce hematopoiesis. PMID 29570934 Huang et al., Journal of Cellular and Molecular Medicine 2018
- Ischemic retinopathy / retinal vascular repair Animal studies only
- In oxygen-induced retinopathy (OIR) mice, systemic ARA-290 reduced IL-1β and TNF-α expression in the mouse retina. The vasoreparative function of intravitreally transplanted ECFCs was enhanced in the presence of ARA-290 but not EPO. ARA-290 activated pro-survival signaling and enhanced ECFC viability under oxidative st PMID 30876881 O'Leary et al., Experimental Eye Research 2019
- Cerebral ischemic stroke / traumatic brain injury Animal studies only
- ARA-290 provided neuroprotective effects in MCAO mouse model comparable to EPO, significantly reducing neuronal apoptosis and inflammatory cytokines in brain tissue. Neuroprotective effect was significantly suppressed by siRNA knockdown of βCR, confirming βCR-dependence. No erythropoiesis was observed. PMID 38488446 Wang et al., CNS Neuroscience & Therapeutics 2024
- pHBSP (ARA-290; 30 µg/kg IP every 12 h for 3 days) in mild TBI rats (started 1 h or 24 h post-injury) significantly improved Morris water maze performance and reduced activated inflammatory cells (CD68) in brain tissue vs. controls. PMID 22827443 Robertson et al., Journal of Neurotrauma 2013
- Cardiovascular aging / cardiac inflammation and frailty (animal) Animal studies only
- Chronic ARA-290 treatment in aged Fischer 344 x Brown Norway rats mitigated age-related increases in cardiac inflammation markers, enhanced cardiomyocyte autophagy flux, reduced lipofuscin accumulation, blunted age-associated blood pressure elevation, preserved LV ejection fraction, preserved body weight, and reduced m PMID 36741836 Winicki et al., Frontiers in Cardiovascular Medicine 2022
- Alzheimer's disease pathology (animal) Animal studies only
- Early systemic ARA-290 administration in young APP/PS1 mice decelerated Aβ pathology progression and improved cognitive functions by specifically stimulating Ly6C-low patrolling monocytes. Effects were absent in aged APP/PS1 mice with advanced pathology and were lost when Ly6C-low monocytes were selectively depleted. PMID 34343617 Al-Onaizi et al., Brain, Behavior, and Immunity 2022
- Bone metabolism / inhibition of osteoclastogenesis Mixed
- One month of cibinetide treatment significantly increased cortical (~5.8%) and trabecular (~5.2%) bone mineral density in C57BL/6J WT female mice. CIB alone or combined with EPO inhibited osteoclastogenesis in vitro and reduced osteoclast progenitors (LinCD11b-Ly6C-hi CD115+) by 42.8% vs. EPO alone in vivo. PMID 35008482 Awida et al., International Journal of Molecular Sciences 2021
- Diabetic macular edema Human observational
- Phase 2 trial (n=9, 8 completed): cibinetide 4 mg/day subcutaneously for 12 weeks. No improvement in mean change in BCVA, CRT, central retinal sensitivity, or tear production. Improvement in NEI VFQ-25 composite scores observed. Some participants showed improvements in CRT, tear production, diabetic control, and albumi PMID 32674280 Lois et al., Journal of Clinical Medicine 2020
- Antidepressant / emotional processing effects Human RCT
- Randomized, double-blind, parallel-group trial (N=36 healthy participants): single ARA-290 2 mg dose vs. placebo. ARA-290 modulated some aspects of emotional processing (lower neural responses to happy faces in fusiform gyrus, increased attention to positive pictures) but the direction and strength of effects did not u PMID 26431906 Cerit et al., European Neuropsychopharmacology 2015
- Hemolytic-uremic syndrome (HUS) Animal studies only
- pHBSP (ARA-290 analog) administration improved 7-day survival and attenuated renal oxidative stress in Stx-induced murine HUS. pHBSP also attenuated renal nitrosative stress and reduced tubular dedifferentiation. No thromboembolic complications or other adverse side effects were observed. PMID 36211426 Dennhardt et al., Frontiers in Immunology 2022
- Preeclampsia (animal model) Animal studies only
- pHBSP at 10 µg/kg and 250 µg/kg corrected morphofunctional disorders in ADMA-like preeclampsia in Wistar rats. Greatest effect at 250 µg/kg: decreased systolic/diastolic BP by 31.2/32.8%, decreased endothelial dysfunction coefficient by 48.6%, increased placental microcirculation by 82.8%, decreased proteinuria by 76.1 PMID 32942669 Korokin et al., International Journal of Molecular Sciences 2020
- Insulin resistance / metabolic syndrome (animal) Animal studies only
- NOTE: This publication is marked as a Retracted Publication in PubMed. pHBSP (30 µg/kg SC) for 11 weeks in HFHS-fed C57BL/6J mice ameliorated insulin resistance, improved renal function, reduced hepatic lipid deposition, and normalized serum glucose and lipid profiles. Results should be interpreted with caution given t PMID 25164531 Collino et al., British Journal of Pharmacology 2014
- Sarcoidosis-associated fatigue Human RCT
- Systematic review of sarcoidosis-associated fatigue interventions identified ARA-290 as one of six evaluated interventions. Evidence base was limited; studies were short in duration with small participant numbers. Further investigation required. PMID 27507833 Atkins & Wilson, Chronic Respiratory Disease 2017
- Type 2 diabetes — executive cognitive dysfunction (animal) Animal studies only
- ARA-290 improved insulin sensitivity and altered circulating monocyte proportions in db/db mice but did NOT rescue deficits in executive cognitive flexibility (reversal learning). RNA-seq revealed hippocampal immune pathway enrichment consistent with chronic low-grade inflammation. PMID 41933665 Alasousi et al., Neurobiology of Disease 2026
Protocol
No community protocol on record. In clinical studies, ARA-290 was dosed at 2 mg (fixed dose) intravenous (3 times weekly) (PMID 23168581).
All studies (36)
- PMID 23168581 Human RCT
Sarcoidosis-associated small fiber neuropathy (SFN) and neuropathic pain - PMID 24136731 Human RCT
Sarcoidosis-associated small fiber neuropathy (SFN) and neuropathic pain - PMID 24555851 Human RCT
Sarcoidosis-associated small fiber neuropathy (SFN) and neuropathic pain - PMID 25387363 Human RCT
Type 2 diabetes — metabolic control and peripheral neuropathy - PMID 26431906 Human RCT
Antidepressant / emotional processing effects - PMID 27507833 Human RCT
Sarcoidosis-associated fatigue - PMID 28475703 Human RCT
Sarcoidosis-associated small fiber neuropathy (SFN) and neuropathic pain - PMID 32674280 Human observational
Diabetic macular edema - PMID 26683514 Mixed
Pancreatic islet transplantation protection - PMID 32345869 Mixed
Pancreatic islet transplantation protection - PMID 34498509 Mixed
Pancreatic islet transplantation protection - PMID 35008482 Mixed
Bone metabolism / inhibition of osteoclastogenesis - PMID 22827443 Animal studies only
Cerebral ischemic stroke / traumatic brain injury - PMID 23262243 Animal studies only
Neuropathic pain (animal models — nerve injury, neuritis, allodynia) - PMID 23302512 Animal studies only
Renal ischemia-reperfusion injury / kidney transplantation protection - PMID 23456872
Not specified numerically in abstract Not specified in abstract (animal) - PMID 24225194 Animal studies only
Renal ischemia-reperfusion injury / kidney transplantation protection - PMID 24518674 Animal studies only
Experimental autoimmune conditions (EAE, EAN, SLE, colitis) - PMID 24529189 Animal studies only
Neuropathic pain (animal models — nerve injury, neuritis, allodynia) - PMID 24603865 Animal studies only
Experimental autoimmune conditions (EAE, EAN, SLE, colitis) - PMID 25164531 Animal studies only
Insulin resistance / metabolic syndrome (animal) - PMID 25728128
- PMID 26774587 Animal studies only
Neuropathic pain (animal models — nerve injury, neuritis, allodynia) - PMID 28688286 Animal studies only
Diabetic wound healing - PMID 29026145 Animal studies only
Experimental autoimmune conditions (EAE, EAN, SLE, colitis) - PMID 29223734 Animal studies only
Diabetic wound healing - PMID 29570934 Animal studies only
Experimental autoimmune conditions (EAE, EAN, SLE, colitis) - PMID 30876881 Animal studies only
Ischemic retinopathy / retinal vascular repair - PMID 32335150
50–400 nM in vitro (in_vitro) - PMID 32942669 Animal studies only
Preeclampsia (animal model) - PMID 34343617 Animal studies only
Alzheimer's disease pathology (animal) - PMID 36085231 Animal studies only
Renal ischemia-reperfusion injury / kidney transplantation protection - PMID 36211426 Animal studies only
Hemolytic-uremic syndrome (HUS) - PMID 36741836 Animal studies only
Cardiovascular aging / cardiac inflammation and frailty (animal) - PMID 38488446 Animal studies only
Cerebral ischemic stroke / traumatic brain injury - PMID 41933665 Animal studies only
Type 2 diabetes — executive cognitive dysfunction (animal)